CAJ | 학술논문

完全切除的非细胞肺癌(NSCLC)是否需要术后辅助化疗是多年来肺癌治疗领域的研究热点,随着各种新药及新的联合化疗方案的出现,几项大型随机临床试验论证了含铂类药物术后辅助化疗可以延长患者生存期,从而奠定了肺癌术后辅助化疗的地位,但目前术后辅助化疗的预后和其疗效预测仍有很多末知因素.
완전절제적비세포폐암(NSCLC)시부수요술후보조화료시다년래폐암치료영역적연구열점,수착각충신약급신적연합화료방안적출현,궤항대형수궤림상시험론증료함박류약물술후보조화료가이연장환자생존기,종이전정료폐암술후보조화료적지위,단목전술후보조화료적예후화기료효예측잉유흔다말지인소.
The post-operative adjuvant chemotherapy for non-small cell lung cancer(NSCLC)has been a highlight around the world.Along with the appearance of each kind of new drugs and new combined therapeutic regimen,several randomized clinical trials have demonstrated a clear survival advantage for patients treated with platin-based adjuvant therapy.Nevertheless,the prognosis and efficiency prediction of postoperative adjuvant chemotherapy is still uncertain at present.